Expand the table to see all examples, or keep it collapsed for a cleaner interface
(For a separate analysis of MEDVi's GLP-1 weight loss program - including pricing structure, compounding classification, and the clinician-supervised prescribing process - read the full MEDVi GLP-1 program overview here
Preclinical data on GLP-1 and GLP-1 RAs have displayed an impressive neuroprotective efficacy in stroke, Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases
First-time prescribing of ADMs decreased in June 2025, relative to March 2025 (- 15.1%)
Chakhtoura, M
The Journey Begins: Initial Effects and Early Signs When starting a GLP-1 medication therapy journey, patients can expect to notice initial effects and early signs of the medications impact on their weight and metabolic health within the first few weeks of treatment